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Abstract: Marine-derived chitosan (CS) is a cationic polysaccharide widely studied for its bioactivity,
which is mostly attached to its primary amine groups. CS is able to neutralize reactive oxygen
species (ROS) from the microenvironments in which it is integrated, consequently reducing cell-
induced oxidative stress. It also acts as a bacterial peripheral layer hindering nutrient intake and
interacting with negatively charged outer cellular components, which lead to an increase in the cell
permeability or to its lysis. Its biocompatibility, biodegradability, ease of processability (particularly
in mild conditions), and chemical versatility has fueled CS study as a valuable matrix component of
bioactive small-scaled organic drug-delivery systems, with current research also showcasing CS’s
potential within tridimensional sponges, hydrogels and sutures, blended films, nanofiber sheets and
fabric coatings. On the other hand, renewable plant-derived extracts are here emphasized, given
their potential as eco-friendly radical scavengers, microbicidal agents, or alternatives to antibiotics,
considering that most of the latter have induced bacterial resistance because of excessive and/or
inappropriate use. Loading them into small-scaled particles potentiates a strong and sustained
bioactivity, and a controlled release, using lower doses of bioactive compounds. A pH-triggered
release, dependent on CS’s protonation/deprotonation of its amine groups, has been the most
explored stimulus for that control. However, the use of CS derivatives, crosslinking agents, and/or
additional stabilization processes is enabling slower release rates, following extract diffusion from
the particle matrix, which can find major applicability in fiber-based systems within ROS-enriched
microenvironments and/or spiked with microbes. Research on this is still in its infancy. Yet, the few
published studies have already revealed that the composition, along with an adequate drug release
rate, has an important role in controlling an existing infection, forming new tissue, and successfully
closing a wound. A bioactive finishing of textiles has also been promoting high particle infiltration,
superior washing durability, and biological response.
Keywords: chitosan; plant extracts; drug delivery systems; nanoparticles; bioactive; electrospun
fibers; medical textiles
1. Chitosan
Chitin is the second most abundant biologically derived polymer worldwide, after
cellulose [1]. It is the primary structural component of the exoskeleton of shrimps, crabs,
lobsters, and squid pens, and is present in smaller amounts in the cell walls of some fungi
and yeast and in plants [2]. This polysaccharide has a chemical structure similar to that of
cellulose, with hydroxyl groups at position C-2 replaced by acetamido groups [3]. Chitosan
(CS) is mainly obtained by partial deacetylation of chitin, under high temperatures and
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alkaline conditions [1,4], when the degree of acetylation (DA, molar fraction of N-acetylated
units) is lower than≈50%. Glucosamine and N-acetylglucosamine are connected through a
1,4-glycosidic bond to form the skeleton of CS, which leads to a linear polymeric structure
(Figure 1) [3,5].
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l c lar eight (Mw) and the DA are its main structural par meters influenci g
the ov rall behavior of the polymer as a biomateri l [2,7]. CS with a wide range of DA and
Mw can be found commercially (DA < 35% and Mw between 10 and 800 kDa), being widely
accepted that low Mw is belo 50 kDa, medium Mw is between 50 and 150 kDa, and high
Mw is superior to 150 kDa [8]. CS is soluble in nearly all diluted aqueous acidic solutions
and insoluble i water, concentrated acid, alkali, alcohol, and acetone and in commo
organic solvents. The polymer can be degraded enzymatically, through chemoenzymatic
ea s, recombina t approaches, and physical means such as electromagnetic radiation
and sonication. In humans, in vivo degradation of CS is thought to be primarily due to
the activity of lysozymes (present in articular cartilage, liver, plasma, saliva, tears, and
milk) and bacterial chitosanolytic enzymes (e.g., chitosanase) that have been identified
in human tissues of the gastrointestinal tract and lung. These enzymes hydrolyze both
glucosamine and acetylated residues, leading to polymer erosion into a suitable size for
renal clearance [2,9].
CS is regarded as a nontoxic and a biologically compatible polymer, extensively stud-
ied for multiple biomedical applications including the formulation of small-scale drug
delivery systems [2,10]. Among its numerous attractive features, mostly connected to its pe-
ripheral groups, notably its primary amines and hydroxyl groups, the polymer inherently
exerts mucoadhesive, haemostatic, chemoattractive, regenerative, analgesic, antioxidant,
and immunomodulatory traits [2,11–13]. Its mucoadhesiveness results in transient opening
of the tight junctions between epithelial cells of the intestinal mucosal barrier to enhance
permeation of drugs, proteins, and food nutrition [14]. Its resemblance to human proteo-
glycans, thus being prone to molecular recognition by living cells or tissues, makes it an
appealing regeneration enhancer [2]. The polysaccharide’s terminal moieties react with
the unstable free and reactive oxygen species (ROS) stabilizing them, namely, CS with
low DA and Mw [7]. A low DA also encourages an anti-inflammatory response [15–17],
with a high DA favouring a pro-inflammatory phenotype that can be useful to counteract
cancer cell invasion [18–20]. Moreover, CS is endowed with antimicrobial capacity and
enhanced ability to regulate gut microbiota towards homeostasis [2,11–13,21]. CS oligosac-
charide (DA = 12% and Mw < 1 kDa) supplementation (while dispersed in water) has
been shown to decrease blood glucose levels and reverse the insulin resistance of diabetic
mice, together with having higher intestinal integrity, and suppressed inflammation and
lipogenesis, thereby contributing to gut microbial balance [22]. CS nanoparticle (NP; di-
ameter (d) ≈ 50 nm, built with CS with DA = 5% and Mw = 220 kDa through undisclosed
methodology) intake exerted a positive influence over the composition of colonic micro-
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biota of weaned pigs [23]. Gut dysbiosis enables pathogens to dominate the gut, mostly
bacteria [24]. Hence, it is worth mentioning that CS’s antibacterial activity is particularly
interesting. It is mainly of electrostatic nature, when its amine groups are protonated
(which traditionally occurs at 9.5 < pH < 6.5, depending on its DA [25]) [26,27]. Two mech-
anisms of antibacterial action have been proposed: presence on the cell surface, forming a
polymer layer preventing substance exchange, interfering with nutrient intake; or CS of
lower Mw reaching the intracellular environment, adsorbing electronegative substances
thereby disrupting the physiological activity of bacteria and killing them. Literature also
highlights a concentration-dependent antibacterial effect of CS [4,6,26]. However, the effect
of the polysaccharide can be limited in basic, or even neutral, environments [25–27]. Con-
sequently, a large number of CS derivatives are being developed, given that its amino and
hydroxyl groups confer the polymer with a high chemical versatility that has been widely
explored to maximize the polymer processability, solubility, pH-responsiveness over a
larger pH range, as well as its antimicrobial efficiency [10]. CS derivatives are easily ob-
tained [3,28], including amine (N-modified) and hydroxyl (O-modified) group substitution
by acylation, carboxylation, alkylation, and quaternization, among others [10,29]. Table 1
reveals the latest trends (between 2020 and 2021) regarding CS and CS derivatives used as
antibacterial agents for biomedical applications. Regulatory approval for the use of CS and
its derivatives in the highlighted fields has required material characterization and produc-
tion consistency, functionality, specifications of the product, material and product safety
profile and analysis using validated methods [30]. CS continues to be widely explored
for its antibacterial features, being incorporated into increasingly complex architectures to
attempt solving multivalent clinical needs. However, despite knowing that a particular
range of DA and/or Mw may enhance CS’s antibacterial capacity [27], the choice behind
CS’s batch selection remains poorly justified, with the polymer’s inherent properties being
poorly characterized as well. However, efforts clearly benefit from CS’s chemical versatility
to create polymeric derivatives with ingenious capabilities, providing added value towards
multiple biomedical applications.
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Table 1. Latest trends exploring the antibacterial capacity of CS or CS derivatives while integrating different processed architectures, including main attributes of the created polymer (DA
and Mw) or its derivatives (name of the derivative, DA, degree of substitution (DS) and Mw), biomaterial-processed structures, afflicted bacteria, and intended application.
CS or CS Derivative
CS-Based Structure(s) AM Features Afflicted Bacteria Intended Application Ref.
DA Derivative DS Mw
23–62% Thymine-modified CS - 154–194 kDa CS porous sponges
Wrinkled and damaged cell walls,
particularly with increased DS, which
increased CS’ solubility and charge








- - - 50–190 kDa
Core [gelatin (GN) +
poly(vinylpolypyrrolidone) (PVP)
+ imipenem/cilastatin]—shell
(CS + poly(ethylene oxide) (PEO)
+ vancomycin) nanofibers
Zone of inhibition (ZoI) of 2.45, 2.90, 2.75,
and 1.85 cm, respectively. CS enabled
controlled release of the antibody for
higher global efficiency.
MRSA, S. aureus, P.
Aeruginosa, and E. coli Wound dressing [32]
≥10% Carboxymethyl CS ≥20% 10–20 kDa
Carboxymethyl CS loaded with
waterborne polyurethane–GN
hydrolysate hydrogel film
ZoI of 12–16 and 16–20 mm, respectively.
Higher activity of higher CS derivative
amount, especially at lower pH.
S. aureus and E. coli Wound dressing [33]





CS films alone were effective against both
bacteria and capable of eradicating all P.
aeruginosa in 1 h (*** p < 0.001). Still,
loaded CS/PVA films showed
significantly improved AM traits in
relation to unloaded films within 2 h
of contact.
S. aureus and P. aeruginosa Wound dressing [34]
15% - - Low
Thyme-oil-loaded
CS-tripolyphosphate (TPP)
microcapsules spray dried onto
linen fabric
>98% growth inhibition due to oil and CS
joint action. E. coli Textile finishing [35]




99.8 and 97.3% bacterial reduction,
respectively, driven by CS’s
cationic nature.
S. aureus and E. coli Textile finishing [36]
15% Quaternized tosyl CS 45–55% - Crosslinked hydrogels of CSderivative and GN
Quaternary CS (replacing primary -OH)
and free amino groups interacted with the
anionic bacterial membrane, and the
lipophilic chain perturbed the
hydrophobic domains of the cell envelope.
Minimum inhibitory concentration (MIC):
128−256, 64−128, 256, 256−512, 64 to 128,
64−128, 64−256, and
256−512 µg/mL, respectively.
MRSA, S. epidermidis, P.
aeruginosa, A. baumannii,
vancomycin-resistant S.
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Table 1. Cont.
CS or CS Derivative
CS-Based Structure(s) AM Features Afflicted Bacteria Intended Application Ref.
DA Derivative DS Mw
15% - - Medium
TPP-crosslinked CS, GN,
potato-starch, and banana peel
powder (BPP) blended films
ZoI of 5–8 (S. aureus) and 9–11 mm
(E. coli), because of the CS and BPP
combined effect.
S. aureus and E. coli Wound dressings [38]
29% - - - CS-coated UV-disinfectedVicryl sutures
Growth inhibition of both bacterial and
fungal pathogens, profound inhibition of
slime formation, and mixed-species
biofilm inhibition, as a result of CS’s
activity. No hyphal formation.
S. epidermidis and
Candida albicans Surgical sutures [39]
10% O-carboxymethyl CS 80% 200 kDa O-carboxymethyl CS andJeffamine porous hydrogel
≥99% bacterial reduction on account of









Full inhibition of bacterial infection in 5 h
and improved wound healing, attributed
to the hydrophilic/hydrophobic nature of
CS derivative.
S. aureus and E. coli Tissue adhesives forwound closure [41]
Quaternized CS 26% -
Crosslinked (carbodiimide
chemistry) quaternized
CS-coated titanium printed cages
ZoI: 15 mm2, 0 CFU/mL, decreased
crystal violet staining, in vivo inhibition
of bacterial growth throughout the entire
observation period (1–5 d), and reduced
bacterial quantity in the extracted cages.
S. aureus Intervertebral fusioncages [42]
15% - - 5–20 mPa.s Spray-dried CBO-loaded CS andgelatin microcapsules
Over 90% growth inhibition until 10
fabric washes. S. aureus and E. coli
Functional finishing of
linen [43]
- - - Medium
Self-assembled nanogels of
gluthathione–silver (Ag)
nanoclusters (NCs) and CS
Improved antibacterial action (>10-fold),
with the well-dispersion of the ultrasmall
Ag NCs in the CS framework protecting
Ag NCs from decomposition and
aggregation and allowing a slow release
of Ag+ ions; the positively charged CS
carrier substantially promotes
Ag–bacteria interaction and the
concomitant Ag bactericidal activity.
S. aureus, E. coli, Bacillus
subtilis, and P. aeruginosa
Theranostic
nanomedicines [44]
21% - - Medium CS-TPP NPs incorporated withincotton fabric via pad-dry-curing
Increased ZoI: ≈20 (S. aureus and B.
subtilis), ≈16 (E. coli and Proteus vulgaris),
≈25 mm (C. albicans and A. Niger) due to
CS-based NP action.
S. aureus, B. subtilis, E. coli,
Proteus vulgaris, C. albicans
and Aspergillus Niger
Textile finishing [45]
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Table 1. Cont.
CS or CS Derivative
CS-Based Structure(s) AM Features Afflicted Bacteria Intended Application Ref.
DA Derivative DS Mw
- - - -
CS-coated PCl microparticles
(MPs) encapsulating Ag NPs,
then entrapped into PVA/PVP
microneedle layers
pH-triggered Ag release enabled 100%
eradication of bacterial bioburdens from
an ex vivo biofilm model in rat skin,
given the feasibility of the loading of
silver NPs into responsive MPs.
S. aureus and P. aeruginosa Biofilm skin infections [46]
- - - - CS hydrogel combined with zincoxide/zeolite nanocomposite
33 and 45% biofilm formation and
metabolic activity reduction, due to a joint
effect from the nanocomposite’s elements.
Significantly decreased gtfB, gtfC, and ftf
reinforcing lower bacterial adhesion.
Streptococcus mutans Dental biofilm control [47]
- Double bond modifiedN-dodecylated CS - -
Macroporous cryogel containing
double bond modified




against both bacteria and killed 99% of
them after 20 min NIR irradiation,
because of the CS derivative and GO.
S. aureus and E. coli Clinical hemorrhageand infection control [48]




~100% antibacterial efficacy, attributed to
the CS derivative permanently cationic
net charge.
E. coli Wound dressings [49]
<25% - - 310–375 kDa Graphene/CS/magnetite NPs
ZoI of 21.3 and 19.3 mm and MIC of 60
and 70 µg/mL, respectively, due to
synergistic antibacterial action of NP
constituents.
ESBL-producing







- N–succinyl CS - 150 kDa PVA/N–succinyl CS/lincomycinporous hydrogels
~100% and ~70% antibacterial efficacy,
respectively, with the antibiotic being
held responsible for most of it.
S. aureus and E. coli Wound dressings [51]
15–25% - - Medium Ag NP-doped multilayeredCS hydrogel
ZoI: ~7 and ~12 mm, promoted by staged
release pattern of Ag NPs based on acid
triggered dissolution of the
multi-membrane layer by layer.
S. aureus and E. coli Implant coating orwound dressings [52]
- Quaternized CS - -
Double-crosslinked oxidized
dextran–dopamine and
quaternary CS with encapsulated
Ag NPs and deferoxamine
15.5 and 20.8% survival rate, plus 3/97%
and 9/91% live/dead cells, respectively,
through the combination of Ag NPs
and HTCC.
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Table 1. Cont.
CS or CS Derivative
CS-Based Structure(s) AM Features Afflicted Bacteria Intended Application Ref.
DA Derivative DS Mw
- Quaternized CS 22% - Protocatechuic-acid-graftedquaternized CS
Excellent antibacterial properties and
showed a satisfactory synergistic
antibacterial effect with
protocatechuic acid.
S. aureus and MRSA Infection control [54]




Increased cell death (17%), following
contact with released essential oil and
CS shell.
Cutibacterium acnes Topical acne treatment [55]
- - - - Thiolated CS/Ag nanowirecomposite hydrogels
Increased ZoI because of CS derivative
and Ag joint action. S. aureus and E. coli Obstetric wound care [56]
8% Fluorinated quaternaryCS - 50–190 kDa Fluorinated quaternary CS
Bacterial cell death in 6 h. MICs of 64 to
512 µg/mL (Gram-positive bacteria) and
128 to 512 (Gram-negative bacteria),
particularly effective against MRSA and B.
subtilis. Fluorination and quaternization
of CS improved its solubility and
antimicrobial activity. Fluorine is the most
electronegative element with a strong
effect on the conformational and
physicochemical properties of
organic compounds.
MRSA, E. coli, P. aeruginosa,
Streptococcus sanguinis,
Salmonella enterica, S.
epidermidis, B. subtilis, and
S. aureus
Infection control [57]
15–25% Mannose-functionalizedCS - Medium
Mannose-functionalized CS
nanosystems
Particular bacterial growth inhibition (4×
lower), anti-adherence (4× lower), and
biofilm disruption (3–6× lower) activity.
Electrostatic interaction disturbed the
bacterial membrane integrity, osmolarity,
and depletion of nutrients. With mannose,
it interacted with bacterial membrane
lectins, interfering with adhesion
and motility.
Multidrug-resistant clinical




15% N-halaminehydantoin-containing CS 56% 250 kDa
N-halamine
hydantoin-containing CS films
0.003% and 0.218% CFU/mL, on account
of the biocidal N–Cl bonds added to the
already antibacterial CS.
S. aureus and E. coli Infection control [59]





Significant growth inhibition in the first
hours of contact, given antibacterial
features of the built coating.
S. aureus and E. coli Sutures [60]
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Table 1. Cont.
CS or CS Derivative
CS-Based Structure(s) AM Features Afflicted Bacteria Intended Application Ref.
DA Derivative DS Mw




>95% bacterial cell death, potentiated by
the quaternized CS moieties. S. aureus and E. coli Wound dressings [61]
- - - - Cellulose acetate nanofiberscoated with CS nanowhiskers
99% growth inhibition due to CS






- N-succinyl CS - Low N-succinyl CS-ZnO NPsconjugated with curcumin
MIC reduction of 25-to-50-fold and
minimum bactericidal concentration
(MBC) reduction of 10-to-40-fold,
respectively, given curcumin addition to
NPs containing CS derivative and ZnO,
all endowed with antibacterial traits.






- - - Medium CS and β-glycerolphosphatehydrogel
In vitro unresponsiveness but clear
in vivo bacterial reduction, as treated
wounds were completely re-epithelialized
and closed on day 14 post-surgery.
A. baumannii Wound dressings [64]
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2. Plant-Derived Biomolecules
Plant extracts are widely used as natural drugs in conventional medicine, given their
high availability from nature (e.g., seeds, bark, wood, roots, leaves, flowers, and fruits),
bioactivity, operating facility, reduced capital costs, and scalability [65,66]. Plants synthetize
a large panoply of structurally different compounds such as simple phenols and phenolic
acids, quinones, flavonoids, tannins, coumarins, terpenes and terpenoids, alkaloids, lectins
and polypeptides, among other phytochemicals, each having a specific and distinct role in
the plant’s bioactivity [66–71]. Some, such as terpenoids, also give plants their odors; others
(quinones and tannins) offer to plants their pigmentation [69]. These biomolecules can exert
strong antioxidant, anticancer, anti-inflammatory, and antimicrobial properties at their site
of action [14,72–75]. Their ability to inactivate free radicals is mostly mediated by phenolic
biomolecules within its composition, namely the hydrogen atoms of the adjacent hydroxyl
groups (o-diphenol), the double bonds of the benzene ring, and the double bond of the oxo
functional group of some flavonoids. They reduce tissue lipid oxidation, this way delaying
aging, decreasing inflammation, oxidative stress, as well as the chances of developing some
diseases, namely cardiovascular pathologies (e.g., myocardial infarction and atherosclerosis),
cancer, metabolic (e.g., diabetes) and neurological disorders (e.g., depression) [14,70,76]. Plant-
based metabolites act as defense mechanisms against invasive microorganisms, insects, and
herbivores. They wield antibacterial activity via multiple mechanisms, acting in consonance
for increased host protection. Their chemical versatility has additionally enabled the synthesis
of a large variety of functionalized skeletons. Modes of action are variable, yet potent [77–80].
Inhibition of cell wall synthesis, permeabilization and disintegration of bacterial peripheral
layers, restriction of bacterial physiology, oxygen uptake and oxidative phosphorylation, efflux
pump inhibition, modulation of antibiotic susceptibility, biofilm inhibition, hindrance of the
microbial protein adhesion to the host’s polysaccharide receptors, and attenuation of bacterial
virulence, are known and acclaimed mechanisms of action of such elements [67,69,70,81].
Compounds such as lectins even allow specific recognition and reversible interaction to
either free carbohydrates or glycoconjugates, without modifying their structure. They may
form ion channels in the microbial membrane or inhibit adhesion of microbial proteins to
host polysaccharide receptors. Hence, they are capable of precipitating polysaccharides and
glycoproteins or agglutinating cells [82–85]. Overall, these changes are mostly induced by
hydrophobic effects, covalent binding and hydrogen binding of their phenolic compounds [69].
The multitarget action of plant extracts, unlikely to induce resistance [86], has the potential
to surpass the current clinical failures posed by traditional antibiotics [66]. Table 2 illustrates
the main classes of antibacterial plant constituents based on the categorization published
by Cowan [69], including the representation of chemical structures of relevant examples.
For instance, gallic acid (a phenolic acid), while loaded into CS-based NPs and dispersed
within collagen and fibrin hydrogels [87], has shown an excellent DPPH (2,2-Diphenyl-2-
picryl hydrazyl hydrate) radical scavenging activity even at the lowermost concentration of
0.05 mg/mL, strongly contributing for a faster re-epithelialization and wound contraction,
qualities that are highly valued for wound dressing applications. In another study [88],
thyme-essential-oil-loaded CS NPs and nanocapsules, rich in thymol and carvacrol (simple
phenols), exhibited an antibacterial action dependent on thymol and carvacrol release rate,
with 100% phenol release in 5 h (rather than 10 h) evoking 50% larger ZoIs, thus reinforcing
their importance in the field. Authors indicated that studies related to mechanism of action
on bacteria were ongoing. A final example described cinnamaldehyde combination with CS
in the form of NPs via Schiff reaction between the free amine groups of CS and the aldehyde
group of the phenylpropanoid [89]. It substantially enhanced CS’s antibacterial capacity,
additionally improving the stability of the CS NPs. The bacterial growth inhibition was
33–34% higher for grafted CS than for the unmodified polysaccharide-based NPs. Lectins and
polypeptides were excluded from the table, given that they have more complex structures
than the other cited classes. Regardless, these proteins or glycoproteins are often positively
charged, with disulphide bonds. Concanavalin A and galectin-1 are well-known examples,
having as ligands Manα1-OCH3 and Gal(β1→4)Glc, respectively [82–85,90].
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Table 2. Main classes of antibacterial plant constituents based on the division proposed by Cowan [69], in addition to representative chemical structures of relevant examples.
Antibacterial Compound
Classes Description Examples Ref.
Phenols and polyphenols
Simple phenols Single substituted phenolic ring
Eugenol
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Table 2. Cont.
Antibacterial Compound
Classes Description Examples Ref.
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3. Chitosan-Based Small-Scaled Particles Loaded with Plant-Derived Biomolecules
Most of the chemical components of plant extracts are, in general, volatile and sus-
ceptible to temperature, light incidence, oxygen- and/or moisture-induced degradation,
thereby losing efficacy [121,122]. In some cases, these can even induce toxicity and allergic
reactions [123]. Small-scaled particles, as drug reservoirs, can bypass the later issues due to
their capacity to control drug delivery and provide effective solutions [121–123].
CS has already been the object of a vast number of very interesting studies, as NP,
MP, particle-, film-, or coating-layer component [34,124–129] or even as reducing agent
of inorganic NPs [130]. However, these formulations have excluded plant extracts from
their composition. Much has also been published on the use of plant extracts as reducing
agents for inorganic NP synthesis, namely silver, gold, zinc, or copper oxide NPs [131–134].
However, organic NPs, templated upon natural or synthetic organic molecules, are more
easily recognized by the host and biodegraded. CS has been extensively explored as a
carrier component of organic drug delivery systems (mostly nanoparticles, NPs) for load,
and release, of plant-derived compounds [135], with hydrophobic biomolecules being
traditionally encased by a CS-based shell, and hydrophilic biomolecules entrapped within
the CS-containing matrix.
Nanoparticulate systems are colloidal-sized particles with diameters ranging from 1 to
1000 nm [136–138]. Their size offers a high surface/volume ratio and the correlation with
structural sizes of biological components: they are small enough to pass through biological
barriers, internalize target cells, and influence a number of cellular processes [139–141].
Loaded NPs can protect the cargo from biodegradation, thus retaining their bioactivity,
extend circulation times, enable their controlled release, and ensure their efficacy at the
target site, using lower doses than if they were to be used in free form [123,142]. Depending
on the method employed for their preparation, nanospheres—matrix-like systems in which
the drug is dispersed within the polymer chains—or nanocapsules—vesicular systems that
are formed by a drug-containing liquid core (aqueous or lipophilic) surrounded by a single
polymeric membrane, can be obtained [143–145]. Ionic gelation is the most commonly
described procedure for CS-based NP production. In short, CS has the ability to func-
tion as a polyelectrolyte, as it is a polymeric macromolecule with charged or chargeable
groups (particularly its primary amine groups) when dissolved in polar solvents (predom-
inantly water) [2]. Ergo, ionic gelation is a self-assembly process driven by electrostatic
interactions between aqueous solutions of charged macromolecules such as CS and small
molecules (like tripolyphosphate, TPP) carrying opposite electrical charges [66,146,147].
It is an easy, versatile, low-cost technology, requiring a simple and easily scaled-up ap-
paratus, enabling multiple biomolecules incorporation with high efficiency, stability, and
controlled release [2,148]. CS-based small-scale particles have also been broadly gener-
ated by emulsification methods. A single emulsion/solvent extraction method is another
frequent example [143–147]. An emulsification protocol (exposure to high energy source:
ultrasound, homogenizer, milling) implies mixing one liquid phase into another totally or
partially immiscible by resorting to stabilizers like surfactants, which are able to reduce the
interfacial tension between the two liquid phases to achieve stability [143,145]. Typically, a
non-water-miscible organic solution of a hydrophobic drug is mixed with preformed poly-
mers into an aqueous phase containing surfactants. Nano-sized organic solvent droplets are
obtained, being templates for nanocarrier assembly. The non-aqueous phase is removed by
evaporation under low pressure or vacuum or by solvent extraction using a large volume of
water, leading to the formation of NPs dispersed in the water phase. Hence, formed NPs are
then collected by centrifugation or filtration and washed with pure water or buffer solution
to remove residual stabilizers and free drug, and freeze-dried for storage [144,145]. Alter-
natively, hybrid techniques like emulsification followed by ionic gelation can be pursued,
so that the hydrophilic particle surface is further stabilized [73,75,149–151]. To encapsulate
hydrophilic drugs, a double emulsion (water-in-oil-in-water) may be formed with the drug
dissolved in the internal aqueous phase [145]. That, however, has not appear in published
work. Figure 2 represents the most commonly employed processing methodologies to
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create small-scaled organic particles with CS as skeletal component and carrying plant
extracts for enhanced biological effect.
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emulsion techniques [2,66,144,145,152].
Table 3 showcases relevant examples of plant-extract-loaded CS-based small-scale
particles for the aforementioned biomedical applications. Most of the research is being
done with low-medium Mw CS and 15 < DA < 25%, used as-received, and processed
in the form of NPs, namely, using ionic gelation, emulsification, or the hybrid top-down
and bottom-up approaches such as emulsification followed by ionic gelation. Integrated
plant extracts are mostly hydrophobic in nature, and encapsulated (or entrapped, litera-
ture is unclear) wi in the NP matrix, even though some of it gets adsorbed to the NPs,
and s me affinity with CS through hydrogen bonding may al o take place [34]. After
a certain amount of time and under certain conditions, the latter traditionally suffers a
burst release while the remainder of the extract gets released over a longer period of time.
Following the electrostatically self-assembly methods of ionic gelation or polyelectrolyte
complexation, pH change (as it occurs after NP incubation in physiological conditions) is
the most appointed trigger for drug release, given that a higher pH will deprotonate the
primary amines of the CS and feed NP matrix disintegration. Notwithstanding, if the NPs
are further stabilized, for instance through the use of trimethylated CS derivatives that
offer pH-independent cationic charges (increasingly evident with higher DS) [119,151,153]
or emulsification [73,75,149–151], thereby reinforcing NP stability, the appointed release
mechanisms are instead driven by diffusion, with a contained matrix swelling allowing
the drug to traverse the NPs and leave them, which is preceded by drug desorption from
the NP peripheral chains. Figure 3 illustrates and summarizes the main paths taken by a
drug to be loaded onto or into small-scale particles (depending on the goal, mechanism,
and kinetic of actuation, and of NP type), which can then be release from them in different
manners and triggered or controlled by multiple stimuli, either acting alone or combined
to function in parallel or one after the other.
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Table 3. CS-based small-scale organic particles loaded with plant extracts for biomedical applications.
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One of the examples presented in Table 3 highlights CS-quinoline NPs loaded with
quercetin, a hydrophobic anticancer plant extract against HeLa cells. The release of the
anticancer drug is controlled by pH fluctuations and showed high cytotoxicity for can-
cer cell proliferation. The results also demonstrated the potential of these CS-based NPs
crosslinked with quinoline derivatives for drug delivery of other therapeutic agents [74].
For application as dietary supplements, CS and poly (γ-glutamic acid) (γ-PGA, an edi-
ble polyamino acid) NPs were loaded with tea catechins, which are potent antioxidant
polyphenolic compounds present in green tea. Following oral administration, the severe
gastrointestinal tract environment poses severe hurdles to the bioactivity of these oxidation-
sensitive compounds. Their encapsulation in NPs solves this problem, and the results
showed an efficient pH-responsive release of tea catechins from the NPs in simulated
gastrointestinal tract media, with an effective antioxidant activity [14]. In the context of
medical textiles, an interesting example depicted emulsion-derived CS NPs crosslinked
with cinnamaldehyde, an extract from cinnamon trees that is also a bactericidal agent. The
results demonstrated antibacterial activity against S. aureus (Gram-positive) and E. coli
(Gram-negative) bacteria. These NPs can coat medical textiles such as wound dressings
or even other antimicrobial sustainable textiles (e.g., sports wears, home textiles, automo-
tive sector) [89]. Another example presented CS emulsion-derived MPs encapsulating
lemongrass or geranium essential oils (EOs) to act against biofilm formation led by Candida
albicans, a commensal fungus yet a dangerous opportunistic pathogen in certain medical
conditions. The minimum inhibitory concentration (MIC) values for loaded MPs were
lower than for unloaded MPs and free EOs. The higher EO-loaded MP biofilm inhibition
percentage demonstrated the efficiency of MPs against C. albicans biofilm formation and
endurance. EO was released by a slow, and sustained, pH-sensitive diffusion process [72].
A final example within the table described CS/TPP NPs synthesized by ionic gelation with
incorporated gallic acid, which is a plant polyphenolic compound with wound healing
properties along with anti-inflammatory, antioxidant, anti-cancer, anti-diabetic, and neuro-
protective activities. With the synthesized NPs, the authors advanced the preparation of
collagen/fibrin scaffold infused with the gallic-acid-loaded CS NPs. The results showed
increased collagen deposition, angiogenesis, epithelialization and fibroblast migration
which culminated in accelerated wound contraction [87]. These results also demonstrated
the potential of the CS NPs to be incorporated in other biomaterial-processed architectures
with suitable properties to facilitate their practical application.
4. Biomedical Applications: Fiber-Based Systems
Numerous processing methodologies exist for polymer phase change from solution
into solid-state fibres, forming continuous monofilament or multifilament yarns or, alter-
natively, short-length staple fibers subsequently blended with natural fibers (e.g., cotton
or wool), or used by themselves to create scaffolding systems [169]. 3D printing and fiber
spinning technologies (e.g., fiber extrusion spinning, melt-spinning, dry-spinning, wet-
spinning, electrospinning) are considered the most prominent techniques in the biomedical
field to generate such fibrous structures [169,170].
Electrospun nanofiber-based systems are particularly appealing [5]. Mats produced by
electrospinning resemble the morphological structure of the extracellular matrix due to their
nanoscale features, are endowed with large surface area per unit volume, and arranged in
a highly interconnected porous architecture, able to easily incorporate biomolecules or NPs
of interest [5,169,171]. Electrospinning is a simple, effective, and versatile method to yield
fibrous structures with fiber diameters ranging between few nanometers to lower than
one micrometer, a size that is difficult to attain using conventional spinning techniques.
Compared to other techniques used for nanofiber production, such as phase separation, self-
assembly, template synthesis, mechanical drawing, melt blowing, hydrothermal processing,
centrifugal force spinning, and bicomponent extrusion, this method is the most effective in
producing nanofibers with a homogeneous structure [5,172,173], thus being the method
of choice for this particular purpose [169,171]. A polymeric solution is injected through
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a needle and directed at a collector (frequently a conductive aluminum plate, which
generates nonwoven structures). Due to the high applied electrical field, the potential
difference created between the needle and collector attracts the polymer to the later while
allowing solvent evaporation to occur along the taken path. The polymeric solution is
this way converted into nanofibers [171]. The use of different polymers, polymer blends,
or nanocomposites made of organic or inorganic materials can modulate the chemical
composition of electrospun membranes. Physical parameters and structures, such as fiber
diameter, mesh size, porosity, texture, and pattern formation can also be maneuvered,
thereby offering numerous possibilities towards electrospun scaffold design that can meet
the demands of an intended application [171,174].
However, most of these fiber-based systems rely on fabrication techniques that heavily
depend on manual intervention, hindering reproductivity and scaling-up, and leading to
high manufacturing costs. Textile technologies are a viable alternative to those approaches,
enabling the production of finely tuned, fiber-based complex constructs with high control
over the design (e.g., size, shape, porosity and fiber alignment), the manufacture and the
reproducibility. They do not involve the use of toxic solvents and allow production on an
industrial scale through spinning, weaving, knitting, non-woven and braided technolo-
gies [175,176]. Afterwards, a textile finishing can be applied to adjust, or determine, certain
characteristics of the textile item: a fabric can be bleached or sterilized for medical use; a
surface can be treated to become hydrophilic or superhydrophobic, depending on whether
moisture absorption or repellency is required by the particular application; in some cases,
like wound dressings, the two sides of the fabric may be tuned to behave differently; and
a textile may be impregnated/coated with an agent(s) to confer specific properties, or to
assist in the uptake or retention properties of the active agent [176].
Different strategies can be used to incorporate plant-extract-loaded particles into
polymer-based solutions to extrude fibers, either by direct (e.g., co-axial spinning) or
indirect (e.g., co-spinning) encapsulation [169]. Additionally, and alternatively, particles
may be immobilized after obtaining the fibers, via entrapment between the fiber yarns
and/or physical/chemical attachment to the fibers [177]. The immobilization of plant-
extract-loaded CS-based organic particles onto fibers, fibrous assemblies, and textile fabrics
can occur via three main types of chemical bonds, similarly as described elsewhere for
the case of biomolecule’s immobilization onto natural fibers [54]: (a) physical adsorption,
(b) physical entrapment, and (c) covalent bonding.
(a) Physical adsorption includes self-assembly methods such as van der Waals interac-
tions, electrostatic interactions, hydrophobic effects, and affinity recognition [152,153];
(b) Physical entrapment of the particles within the fabric’s fibrous structure takes place
either by vacuum induction or assisted by intermediary adhesive layers [154–157];
(c) Covalent bonding comprises short-range intermolecular attractive forces at the molec-
ular scale [158–160].
There are frequently encountered combinations between the latter approaches, as
well. On the other hand, the immobilization method trends of the aforementioned particles
include the dip-pad-dry-cure method, impregnation, exhaustion method, spray-drying,
and covalent chemistry. The goal is to immobilize a sufficient number of compounds in the
fibrous templates, giving it enough bioactivity, for the necessary time period [54,161].
Fibers and textiles have been widely exploited as pharmaceutical repositories (e.g.,
drug-loaded carriers for medical therapy, nucleic acid delivery for gene therapy, enzyme
carriers for biomedical applications), components of wound dressings (e.g., gauze, foam,
hydrogels, transparent films, alginates, hydrocolloids, and antimicrobial dressings) and
anti-adhesion membranes, percutaneous access devices, implantable devices (e.g., vascu-
lar stents and grafts, sewing rings, hernia repair meshes, skin/bone/cartilage/ligament
mimetic scaffolds, nervous conduits, as well as drug delivery systems), sensors, reinforc-
ing fillers, sound absorption, filtration systems, electrodialysis separation, or as part of
personal protective equipment (PPE) and clothing (e.g., masks, surgical gowns, aprons,
gloves, clothing, and hospital linen) [169,175,176,178]. The so-called biotextiles, based
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on natural and synthetic fibers, are defined as “structures composed of textile fibers and
designed for uses in a specific biological environment where their performance depends
on their interactions with cells and biological fluids as measured in terms of biocompat-
ibility and biostability” [169,175]. These functional textiles are therefore designed and
produced for their technical properties and performances, besides apparel and aesthetic
purposes [179,180].
While facing all the above cited strategies and taking into consideration the aforemen-
tioned content of CS or plant extracts alone and the combination of CS as carrier skeleton
and plant extract as payload, the integration of plant-extract-loaded CS-based organic par-
ticles into fiber-based systems gathers great potential for biomedical applications. Table 4
presents a comprehensive representation of existing studies on this subject.
Co-spun poly(ε−caprolactone) (PCL)/CS/curcumin nanofibers were fabricated by
electrospinning, yielding nanofibers of ≈100 nm in diameter [172]. Then, curcumin-loaded
electrostatically self-assembled CS/TPP NPs (via ionic gelation creating round-shaped NPs,
with d≈ 32 nm) were electrosprayed onto the surface of the previously prepared nanofibers,
to improve the sustained release of curcumin at the wound site. Indeed, loaded nanofibers
exhibited appropriate tensile mechanical properties, swelling behavior and water vapor
transmission rate for use as wound dressing. In vitro testing revealed adequate degradation
rate, curcumin release profile (22% in 6 h, 49% in 72 h), antioxidant potency, antibacterial
efficiency (99.3 and 98.9% growth inhibition of MRSA and extended spectrum β-lactamase
producing E. coli after 48 h), further allowing survival and proliferation of human dermal
fibroblasts. In vivo studies showed 96.25% and 98.5% murine wound closure in 15 days,
with and without MRSA infection. Bacterial growth inhibition was clearly perceived,
enabling an enhanced reparative process of the skin, with well-organized connective
tissue formation devoid of inflammation. Another example also resorted to curcumin-
loaded CS/TPP NPs, this time freeze-dried and then dispersed into a PCL/gelatin (GN)
solution prior to co-spinning [181]. This led to homogeneously distributed NPs of 359 nm
of diameter and −10.7 mV of ζ potential and nanofibers with 1548 nm of diameter and
suitable porosity (65%). Mats were endowed with good mechanical strength to act as
a wound dressing material, in addition to a high swelling capacity, degradation profile,
sustained drug release (23% in 6 h, 100% in 106 h), cytocompatibility towards human
endometrial stem cells (favorable cell adhesion, proliferation and metabolic activity), and
wound healing (82% wound closure at day 14). New tissue resembled normal skin, a
regenerated wound, with clear re-epithelialization, normal rete ridges, and rejuvenation of
skin appendages. Adding the stem cells to the mixture further decreased inflammatory
signals and promoted angiogenesis. These studies show that dressings are in fact an
essential part of the healing process, protecting the wound and intervening actively in the
healing process [182].
Coaxial electrospinning was the strategy selected elsewhere [183] with PCL as core
and polyvinylpyrrolidone (PVP)/veratric-acid-loaded CS/TPP NPs in the outer layer, to
create nanofibrous mats encouraging bone tissue formation. Spherical NPs, with diameters
ranging from 99 to 107 nm (and ζ potential of 16–18 mV), were found to increase nanofiber’s
diameter up to ≈515 nm having clearly defined outlines, plus displaying commendable
swelling and degradation behavior, mechanical properties, biomineralization efficiency,
and in vitro drug release capacity (≈60% in 20 days). In vitro cell culture studies with
mouse mesenchymal stem/stromal cells (mMSCs) resulted in valuable cytocompatibility,
and osteoblastic differentiation potential (proven by alizarin red and von Kossa staining
after 14 days of incubation, and gene expression levels of RUNX2, ALPL, COL1A1, and
BGLAP at day 7 of contact with the biomaterial’s constructs). A different study, also aim-
ing at bone regeneration, co-spun sinapic-acid-loaded CS/TPP NPs with PCL solution,
which were also comprehensively characterized, and yielded exciting results in vitro with
mMSCs and in an in vivo rat model including a critical-sized calvarial bone defect [184].
The cytocompatible constructs encouraged staining of alkaline phosphatase and calcium
phosphate deposits, osteogenic potential at the gene and protein levels (runx2, type I colla-
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gen and osteocalcin) through probable activation of the TGF-β1/BMP/Runx2 signaling
pathway. Micro-computed tomography imaging revealed significant new bone formation
with the optimized constructs at 4 weeks, while histological staining (hematoxylin-eosin
and Masson’s trichrome staining protocols) corroborated the later findings, leaving no
doubt regarding their potential bone neotissue formation. The self-healing capacity of bone
is widely used to recover from small tissue injuries. However, bone grafts are needed to
provide support, fill lacunae, and enhance biological repair/regeneration when the skeletal
defect reaches a critical size [185].
Plant extract-loaded NP-mediated functionalization has also been widely applied to
textile fabrics, with the main goal of obtaining prolonged biological effects [186]. One exam-
ple explored citronella oil encapsulated within CS-based emulsions (having 79–93 nm in
size on the course of 14 days of storage) further stabilized with citric acid onto a cotton knit
(100% cotton textile, pore surface area of 20–90 µm2, distances within interyarn: 10–70 µm,
distances within interfiber (intrayarn): 2–6 µm, and distances within pore (interfiber):
10–90 nm). Prior to particle immobilization through impregnation, the fabric was care-
fully washed and degassed by negative pressure. The results showed that nanocapsules
were able to infiltrate the spacing of cotton textile fibers, including the fiber pores, thus
leading to high washing durability (29% retention after 10 washing cycles). Others [187]
included lemongrass oil loaded into emulsified CS NPs further physically-crosslinked with
TPP (d ≈ 90 nm), which were then imprisoned into cotton fabric (plain-weave 112 g/m2,
60 ends per inch × 58 picks per inch) via dip-dry-curing while aimed at developing a
durable anti-mosquito textile finishing. Acrylate was added as fabric adhesive to retain
the nanogels adhered to the textile fibers. The roughness on fabric groves was maintained
on the surface after dry and wet crocking, with the artificial sweat (acidic and alkaline)
treated fabrics also retaining the roughness due to presence of the capsules. Efficacy was
proven even after 15 washing cycles, still enabling 75% of repellency against mosquitoes
following the activity of the entrapped compounds (100% bioactivity without washing).
Additionally, given that 36 days of repeated application of nanogel on mice’s skin was
nontoxic, the tested formulation was found to be suitable as protective clothing of military
personnel and individuals at risk for mosquito bites in the line of duty. Of particular note is
the extra caution that these recently published studies had with fabric pre-immobilization
procedures, particularly in appropriately washing it so that no contaminants compromised
the intended subsequent bond formations nor the fabric’s applicability. Finally, one last
example [188] emphasizes the value of functional and antimicrobial textile fabrics by im-
mobilizing such herbal nanotechnologies, given that nearly half of the medical textiles
dwell around antimicrobial treatments [176]. A pad-drying approach was used to coat the
cotton fibers with the plant-derived (Aloe vera nano-sized powder) CS NPs (d ≈ 40 nm),
leading to a conglomerate with UV-blocking properties (while exhibiting absorbance in the
UV region at 269 nm, and having UPF > 50), antibacterial activity (ZoIs of ≈27 mm and
≈22 against S. aureus and E. coli, respectively, being close to the results obtained with the
antibiotic amoxicillin (ZoIs of ≈28 mm and ≈23)), and superhydrophobicity (≈155◦), even
after 10 washes.
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5. Conclusions and Future Perspectives
In the biomedical field, recent studies (between 2020 and 2021) mostly exploit CS
and plant extracts forming nanocomposites, directed at infection prevention or control,
additionally acting against oxidative stress and inflammation overload, which are critical
for instance in immunocompromised patients [196–203]. CS is a marine-derived cationic
polysaccharide, approved by the FDA (Food and Drug Administration) for wound dressing
applications and cartilage repairing formulations. It has been approved as functional food
in some Asian countries, recognized as safe (GRAS) and approved for dietary use in Italy
and Finland [177]. Its biocompatibility, bioactivity, chemical versatility, and ease of process-
ing into a variety of structures make it a strong contender for use in numerous biomedical
applications, including microbicidal approaches. As communicable diseases threaten to
reach epidemic proportions, affecting patients from all ages, societal and financial status,
with high mortality rates and healthcare burden, the search for effective antimicrobial
strategies is highly needed. In parallel, plant extracts (widely used as folk medicine) are
increasingly considered as potential alternatives to antibiotics, having high potential for
being a source of natural drugs that can be used to counteract microbial survival and pros-
perity [22,54,55]. Several natural drugs have already been approved for clinical use, namely
for antioxidant and antimicrobial purposes [178,179]. Notwithstanding, their combination
as organic particles has also been object of several studies, while emphasizing their antiox-
idant [158,204,205] and antimicrobial capabilities [204,206,207]. If loaded into CS-based
nano- or micro-scale organic particles [115], plant extracts hold the power to confer strong
and long-lasting effects, without the consequences of overdose-induced tissue damage or
inefficiency due to drug biodegradation ahead of reaching the target site. Their integration
into suitable carriers can protect the drug from biodegradation, transport it into the target
site, enable a controlled release and avoid off-target action, thus heightening, or comple-
menting, their biological effects [2,180,181]. CS-based small-scale organic carriers have
been widely studied for biomedical applications, having tremendous potential [2,182,183].
However, the development of plant-extract-loaded formulations is still limited, namely
when applied to fiber-based systems. Nowadays, electrospinning is the most frequently
studied technique to produce fibers (nanoscale) carrying these NPs, namely via co-spinning.
The compositions are being mainly sought out for wound dressing layers additionally
encouraging tissue regeneration. Large bone lesions may also benefit from such strategies.
On the other hand, cotton is currently the sole type of fabric being functionalized with these
types of particles, with no major pre-treatment being applied. Particle addition is mostly
done by dip-pad-dry-cure method, frequently with citric acid acting as linker between CS
and the cotton fibers, and the particles being produced via emulsification followed by ionic
gelation methods encapsulating the hydrophobic plant extracts. An antimicrobial finishing
has been the major added functionality. However, poor mechanical properties, washing
durability, and burst release are still frequently encountered obstacles. Yet, research is
progressing very well, with the production of numerous and clever CS derivatives, added
processing methodologies, crosslinking steps, and functionalization protocols, thus creat-
ing high hopes to overcome these limitations and stick to its beneficial traits. Moreover,
triggers such as ionic strength, temperature shifts, enzymatic reactions, oxidative stress,
or even light irradiation, not as explored in this context, could also lead to thrilling new
avenues of plant-derived drug consumption under the appropriate pathological settings.
These scientific advancements can be of great utility to produce safe and effective bioactive
medical textiles. Scaffolding systems, coatings, wound dressings, sutures, face masks, and
hospital linen are a few relevant examples.
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